Cutaneous T‑Cell Lymphoma (Mycosis Fungoides)

Overview

Cutaneous T‑cell lymphoma (CTCL) is a rare group of non‑Hodgkin lymphomas that arise from malignant T‑lymphocytes and primarily involve the skin. Mycosis fungoides (MF) is the most common form of CTCL, accounting for about 50‑60 % of cases. The disease typically progresses slowly, beginning with flat, scaly patches that can resemble eczema or psoriasis and may evolve into thicker plaques or tumors over many years. Although MF is usually confined to the skin for a long time, it can eventually spread to lymph nodes, blood, or internal organs in advanced stages. [Mayo Clinic][CDC]

Symptoms Checklist

• Persistent, itchy, scaly patches (often on the trunk, buttocks, or thighs)
• Red or pink patches that may be slightly raised
• Thickened plaques that feel leathery or “cobblestone”‑like
• Raised tumors or nodules that may ulcerate
• Hair loss in affected skin areas
• Changes in skin color or texture
• Swollen lymph nodes (in later stages)
• Unexplained weight loss, night sweats, or fatigue (signs of systemic spread)

Risk Factors

• Age > 55 years (most cases are diagnosed in older adults)
• Male gender (slightly higher incidence than females)
• Long‑standing inflammatory skin conditions (e.g., chronic eczema, psoriasis)
• Exposure to certain chemicals (e.g., industrial solvents, pesticides) – data are limited
• Family history of lymphoma or other hematologic cancers
• Immunosuppression (organ transplant recipients, HIV infection)

Sources: Cleveland Clinic, NIH

Diagnosis

Diagnosing MF requires a combination of clinical evaluation, skin biopsies, and laboratory studies:

1. Clinical examination – Dermatologist assesses lesion morphology and distribution.
2. Skin biopsy – Multiple 4‑mm punch biopsies are taken; histopathology looks for atypical epidermotropic T‑cells.
3. Immunohistochemistry – Stains for CD3, CD4, CD7 loss, and other T‑cell markers help confirm malignancy.
4. Molecular studies – T‑cell receptor (TCR) gene rearrangement PCR can demonstrate clonality.
5. Staging work‑up – Includes blood tests, flow cytometry, imaging (CT or PET‑CT), and sometimes bone‑marrow biopsy to assess extracutaneous spread.

References: Johns Hopkins, Mayo Clinic

Treatment Options

Treatment is individualized based on disease stage, lesion location, patient age, and comorbidities.

Skin‑directed therapies (early‑stage MF)

• Topical corticosteroids – Reduce inflammation and itching.
• Topical retinoids (e.g., bexarotene) – Promote differentiation of malignant T‑cells.
• Topical chemotherapy – Nitrogen mustard or carmustine.
• Phototherapy – Narrow‑band UVB or PUVA (psoralen + UVA) is highly effective for patches/plaques.
• Localized radiation – Low‑dose electron beam for isolated lesions.

Systemic therapies (advanced disease or refractory cases)

• Oral retinoids – Bexarotene, acitretin.
• Interferon‑α – Immunomodulatory, often combined with retinoids.
• Histone deacetylase (HDAC) inhibitors – Vorinostat, romidepsin.
• Monoclonal antibodies – Brentuximab vedotin (targets CD30‑positive lesions).
• Targeted agents – Mogamulizumab (anti‑CCR4), pembrolizumab (PD‑1 inhibitor) in selected patients.
• Chemotherapy – CHOP or gemcitabine‑based regimens for transformed disease.
• Allogeneic stem‑cell transplant – Considered in very high‑risk or refractory cases.

Supportive & home care measures

• Gentle skin moisturizers (fragrance‑free, hypoallergenic) to maintain barrier function.
• Cool compresses or antihistamines for pruritus.
• Avoidance of skin irritants (harsh soaps, tight clothing).
• Sun protection – broad‑spectrum sunscreen SPF 30+; phototherapy is supervised, not self‑administered.
• Regular follow‑up with dermatology/oncology to monitor disease activity.

Sources: Cleveland Clinic, NIH

Prevention

Because MF’s exact cause is unknown, primary prevention is limited. However, risk can be reduced by:

• Managing chronic inflammatory skin conditions promptly and effectively.
• Limiting exposure to known occupational chemicals (use protective equipment).
• Maintaining a healthy immune system – balanced diet, regular exercise, adequate sleep.
• Avoiding unnecessary immunosuppressive medications when possible.
• Regular skin examinations, especially for individuals with longstanding eczema or psoriasis.

Living With Cutaneous T‑Cell Lymphoma (Mycosis Fungoides)

• Skin care routine: Use lukewarm water, mild cleansers, and apply moisturizers within 3 minutes of bathing.
• Pruritus control: Keep nails trimmed, use cool showers, and consider prescription antihistamines or gabapentin if itching is severe.
• Psychosocial support: Join patient support groups (e.g., Lymphoma Research Foundation) and consider counseling to address anxiety or body‑image concerns.
• Physical activity: Low‑impact exercises (walking, yoga) improve circulation and overall well‑being.
• Nutrition: Emphasize anti‑inflammatory foods (omega‑3 fatty acids, fruits, vegetables) and stay hydrated.
• Medication adherence: Keep a medication calendar; discuss side‑effects with your care team promptly.
• Regular monitoring: Attend scheduled skin checks, blood work, and imaging as recommended.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe swelling of the face, lips, or throat (possible anaphylaxis from a medication).
• Rapidly spreading ulcerated skin lesions with foul odor or signs of infection (fever > 38.3 °C, chills).
• Unexplained, persistent high fever or night sweats accompanied by weakness.
• Severe, new‑onset shortness of breath or chest pain (possible pulmonary involvement).
• Sudden, unexplained bruising or bleeding (possible bone‑marrow involvement).